Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Atezolizumab and Bevacizumab Pre-Liver Transplantation for Patients With Hepatocellular Carcinoma Beyond Milan Criteria
NCT05185505Phase 4Enrolling by invitation
- Sponsor
- Houston Methodist Research Institute
- Start
- Jan 2023
- Primary completion
- Apr 2027
- Modality
- Monoclonal Antibodies
- Countries
- 2
01
Overview
A Phase 4 trial of atezolizumab, bevacizumab in hepatocellular carcinoma (HCC), sponsored by Houston Methodist Research Institute. Started Jan 2023; status: enrolling by invitation.
02
Drugs
atezolizumabbevacizumab
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT05185505.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05185505.